MedTrace Logo

Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer

NCT00388154 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2014-11-13

Study results available
· View outcomes & findings →

Summary

Primary Objective:

* To estimate the antitumor activity of the combination of gemcitabine and cisplatin in patients with advanced (stage III or IV) or recurrent endometrial cancer.

Secondary Objective:

* To determine the nature and degree of toxicity of the combination of gemcitabine and cisplatin in this cohort of patients.

Conditions

Interventions

DRUG

Gemcitabine

900 mg/m\^2 by vein over 1 hour on Day 1 and Day 8.

DRUG

Cisplatin

30 mg/m\^2 by vein over 1 hour on Day 1 and Day 8.

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Jubilee Brown, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-08-31
Primary Completion
2013-11-30
Completion
2013-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00388154 on ClinicalTrials.gov